Pfizer breast cancer drug gets early FDA approval
Federal health regulators have approved a highly anticipated medicine from Pfizer Inc to treat postmenopausal women with a certain type of advanced breast cancer who have not already taken other drugs.
The Food and Drug Administration yesterday approved Ibrance for women who have tumors that do not contain a protein known as HER-2. Ibrance, known generically as palbociclib, works by blocking molecules linked to cancer cell growth.
Pharmaceutical industry analysts expect Ibrance to grow into a mega-blockbuster, with annual sales as high as USD 4 billion by 2020.